Prelude Therapeutics annual operating margin
2024
2025
Prelude Therapeutics Operating Margin Growth & History (PRLD)
Prelude Therapeutics's operating margin was −861.33% for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −861.33% | +1134.58 pp |
| 2024 | 2024-12-31 | −1,995.91% | — |
Prelude Therapeutics quarterly operating margin
Q3.24
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −270.93% | — |
| Q1 2026 | 2026-03-31 | −309.54% | — |
| Q4 2025 | 2025-12-31 | −307.59% | — |
| Q3 2025 | 2025-09-30 | −314.12% | +831.74 pp |
| Q3 2024 | 2024-09-30 | −1,145.87% | — |
Prelude Therapeutics operating margin trends
Between the periods ended 2024-12-31 and 2025-12-31, Prelude Therapeutics's operating margin increased from −1,995.91% to −861.33%, a change of +1134.58 percentage points. The latest reported quarter, Q2 2026, shows −270.93%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...
